
An extended-release version of a Parkinson’s disease drug could provide more stable relief for patients with the movement disorder, new clinical trial data show. The new formulation of levodopa, called IPX203, extended the duration of patients’ “on time” — the amount of time the medication is working and symptoms are lessened, researchers reported this week… read on > read on >